NewStem vs OncoDecipher
NewStem vs OncoDecipher, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: NewStem is on 45/100 and OncoDecipher on 43/100.
Where each one leads
NewStem
- funding raised: $30.0M against $1.0M
OncoDecipher
Leads on none of the measures we hold for both companies.
At a glance
| Measure | NewStem | OncoDecipher |
|---|---|---|
| What it is | Biopharmaceutical company developing human haploid stem cells for regenerative medicine and disease therapy. | OncoDecipher uses silent mutations in cancer genomes to predict cancer type and survival probability. |
| Category | Life Sciences, Biotech, Biopharmaceutical, MedTech | Life Sciences, Cancer, Oncology, Mutation |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Software |
| Founded | 2018 | 2015 |
| Headquarters | Rehovot, Israel | Cambridge, United States |
| Status | Active | Inactive |
Size, funding and growth
| Measure | NewStem | OncoDecipher |
|---|---|---|
| Total funding | $30.0M | $1.0M |
| Latest round | Series B | Seed |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | NewStem | OncoDecipher |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 45/100 | 43/100 |
| Traction | 37/100 | 30/100 |
| Team | 30/100 | 60/100 |
| Search visibility | 9/100 | 3/100 |
| Quality | 58/100 | 52/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (50/100) | Not published |
| Domain ratingLink authority, 0-100 | 4/100 | Not published |
NewStem vs OncoDecipher: common questions
Which is better, NewStem or OncoDecipher?
On our 0-100 score NewStem rates higher (45/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do NewStem and OncoDecipher compare on the numbers?
NewStem leads on funding raised ($30.0M against $1.0M).
Read the full NewStem review and pricing or the OncoDecipher review and pricing. You can also browse other NewStem alternatives we track.